Sirios Capital Management L P Decreases Position in Natera, Inc. $NTRA

Sirios Capital Management L P lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 16.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,486 shares of the medical research company’s stock after selling 2,539 shares during the period. Sirios Capital Management L P’s holdings in Natera were worth $2,109,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna purchased a new position in shares of Natera in the second quarter valued at about $1,235,000. WINTON GROUP Ltd bought a new stake in Natera during the 2nd quarter worth approximately $558,000. California Public Employees Retirement System grew its holdings in Natera by 15.6% during the 2nd quarter. California Public Employees Retirement System now owns 217,422 shares of the medical research company’s stock valued at $36,731,000 after buying an additional 29,296 shares in the last quarter. Cerity Partners LLC increased its stake in Natera by 13.9% in the 2nd quarter. Cerity Partners LLC now owns 97,573 shares of the medical research company’s stock worth $16,484,000 after acquiring an additional 11,928 shares during the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Natera by 14.9% in the 2nd quarter. Federated Hermes Inc. now owns 767,813 shares of the medical research company’s stock valued at $129,714,000 after acquiring an additional 99,789 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NTRA. BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a report on Monday, October 27th. UBS Group raised their price objective on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Piper Sandler raised their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, BTIG Research increased their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $225.29.

Natera Trading Down 1.5%

NTRA opened at $235.53 on Wednesday. The company has a market capitalization of $32.58 billion, a price-to-earnings ratio of -102.85 and a beta of 1.63. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $246.90. The business’s fifty day simple moving average is $202.57 and its 200-day simple moving average is $175.16.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period last year, the company earned ($0.26) earnings per share. The firm’s revenue was up 34.7% compared to the same quarter last year. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In related news, Director Roelof Botha sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the transaction, the director owned 1,154,198 shares of the company’s stock, valued at $272,529,231.76. The trade was a 6.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider directly owned 117,559 shares in the company, valued at $18,808,264.41. This trade represents a 2.49% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 312,053 shares of company stock valued at $64,527,735. 5.63% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.